|
Source and description of samples used in the study |
||||||
| Sample source |
Disease |
Number |
Female, no. (%) |
Age (range) |
anti-CCP positive, no. (%) |
RF positive, no. (%) |
|
|
||||||
| Dr. P. Gregersen, plasma set 1 |
RA |
30 |
28 (93) |
72.6 (51 to 89) |
20 (67) |
24 (80) |
| Healthy |
10 |
|||||
|
|
||||||
| Dr. P. Gregersen, plasma set 2 |
IBD |
20 |
13 (65) |
46.4 (23 to 82) |
||
| JRA |
20 |
16 (80) |
37.3 (10 to 71) |
6 (30) |
6 (30) |
|
| PsA |
14 |
11 (79) |
52.6 (23 to 75) |
|||
| PS |
20 |
10(50) |
55.3(22 to 86) |
|||
| RA |
20 |
19(95) |
59.0(35 to 89) |
|||
| SLE |
20 |
13 (65) |
51.3 (29 to 67) |
|||
|
CCP, cyclic-citrullinated peptides; RF, rheumatoid factor; RA, rheumatoid arthritis; IBD, inflammatory bowel disease; JRA, juvenile rheumatoid arthritis; PsA, psoriatic arthritis; PS, psoriasis; SLE, systemic lupus erythematosus. | ||||||
Zhao et al. Arthritis Research & Therapy 2008 10:R94 doi:10.1186/ar2478 |
||||||